Ugoos X5M Pro is a TV box based on Amlogic S905X5M chipset, which is one of the new budget chipsets from Amlogic (no VCC/H.266 support for instance). This box is similar if not identical to it’s older brothers from X4 family (reviewed here in the past), and the specs are simply upgraded. Aside for BT …
Ugoos AM9 is Ugoos’ newest offering, but like with SK series (SK1 to SK2), it takes a step back. From the powerful AM6 Pro and the AM8 (not sure where AM7 went), it goes to a cheaper chipset (Amlogic S905X5) with lighter specs. Many thanks goes to James from Ugoos for providing the AM9 Review …
Ugoos SK2 is Ugoos’ new budget Android TV box, and it’s a bit different than their other boxes. The biggest difference is the OS. SK2 uses Google Android TV at its core, and a realtek RTD1325 chipset. All of that is done to keep costs down, while still including licensing for the big streaming services. …
Genetic screening that identifies cancer-linked mutations in newborns could give doctors a head start on treatment, but it comes with risks. Read More
Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04619-9 Editorial Expression of Concern: Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury Read More
Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04568-3 Automated visual evaluation (AVE) could be transformative for cervical cancer screening in low-resource settings. However, AVE research has yet to yield robust clinical tools. Frugal approaches are needed that emphasize efficient, multimodal models, explainable outputs, local calibration and evaluation in real-world screening workflows. Read More
Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04582-5 Once seen as a symptom, disrupted sleep is emerging as a modifiable driver of chronic illness. Drugmakers are targeting sleep pathways to reshape chronic disease biology, from pain to depression. Read More
Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04564-7 In a multicenter, phase 2 trial, patients with treatment-naive locally advanced unresectable or metastatic triple-negative breast cancer were treated with the PD-1/vascular endothelial growth factor bispecific antibody ivonescimab plus chemotherapy, resulting in encouraging preliminary objective response rates, which support further testing in a large, randomized, phase 3 …